Brimonidine for managing ocular hypertension and glaucoma

Article

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension, from the December 2008 issue of Clinical Ophthalmology.

Please click here to read the abstract.

Related Videos
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Colman Cawe, director of fundraising and communications, Orbis UK
Greg Kunst, CEO of Aurion Biotech
Related Content

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

September 12th 2023

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

September 12th 2023

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Syncona announces Novartis will discontinue development of GT005 for geographic atrophy

September 12th 2023

Bausch + Lomb launches MIEBO (perfluorohexyloctane ophthalmic solution) in US

September 12th 2023
© 2023 MJH Life Sciences

All rights reserved.